Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06980649 · ClinicalTrials.gov registry record · Phase 1
Study of BHV-1300 in Graves' Disease
A Phase 1 study of Graves Disease, sponsored by Biohaven Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 13
- Study locations
NCT06980649: Recruiting Phase 1 study of Graves Disease, sponsored by Biohaven Therapeutics.
NCT06980649 is a Phase 1 study of Graves Disease that is actively recruiting participants, run by Biohaven Therapeutics. The registered enrollment target is 15 participants, below the 308-participant average among 11 other Graves Disease trials with a reported enrollment target (95% lower). The trial reports 13 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06980649, a Phase 1 study of Graves Disease, is actively recruiting participants, sponsored by Biohaven Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Primary Outcome
To assess the safety and tolerability of BHV-1300. This objective will be measured by assessing the number of unique subjects with SAEs, AEs leading to discontinuation or deaths that are observed during the Open-label Treatment Phase (up to 52 weeks).
Conditions Studied
Interventions
- DRUG BHV-1300
Study Locations (13)
Other
- Site-004 - Fitzroy
- Site-001 - Kotara
- Site-003 - Melbourne
- Site-010 - Oaklands Park
- Site-008 - Parkville
- Site-006 - St Leonards
- Site-002 - Torquay
Texas
- Site-106 - Houston
- Site-101 - Houston
- Site-105 - Shavano Park
California
- Site-103 - South Gate
Florida
- Site-100 - Miami
Georgia
- Site-104 - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-08-21 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What NCT06980649 shows while recruiting
NCT06980649 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 308-participant average among 11 other Graves Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Graves Disease appearing as the primary indexed condition, and to 1 intervention - of which BHV-1300 is the first listed.
NCT06980649 lists 13 locations in 5 states (Other, Texas, California).
Frequently Asked Questions
What is clinical trial NCT06980649 about?
NCT06980649 is a clinical study titled "Study of BHV-1300 in Graves' Disease". The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
What is the current status of trial NCT06980649?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-08-21. Estimated completion is 2026-09.
What conditions does trial NCT06980649 study?
This clinical trial studies the following conditions: Graves Disease.
What interventions are being tested in trial NCT06980649?
The interventions under investigation include: BHV-1300 (DRUG).
Who is sponsoring clinical trial NCT06980649?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06980649 being conducted?
This trial has 13 study locations across California, Florida, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graves Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06980649's enrollment target sits among peer trials
15 10th of 11 higher than 1 of 11 other Graves Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graves Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
RECRUITING · Phase 1
-
Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
RECRUITING · Phase 2
-
Personalized Treatment in Thyroid Disorders
RECRUITING · NA
-
Preoperative Corticosteroids in Autoimmune Thyroid Disease
RECRUITING · Phase 4
-
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RECRUITING
-
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI